NK Cell-based Cancer Immunotherapy: from Basic Biology to Clinical Development

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2021 Jan 7

PMID 33407739

Citations 282

Authors

Sizhe Liu

Vasiliy Galat

Yekaterina Galat

Yoo Kyung Annie Lee

Derek Wainwright

Jennifer Wu

Affiliations

Soon will be listed here.

Abstract

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.

Citing Articles

Immunological Effects of Proton Radiotherapy: New Opportunities and Challenges in Cancer Therapy.

Zhang A, Fan L, Liu Q, Zuo X, Zhu J Cancer Innov. 2025; 4(2):e70003.

PMID: 40061827 PMC: 11885950. DOI: 10.1002/cai2.70003.

A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells.

Yi E, Lee E, Park H, Lee H, Yun S, Kim H J Exp Clin Cancer Res. 2025; 44(1):86.

PMID: 40045373 PMC: 11884141. DOI: 10.1186/s13046-025-03351-5.

Boosting tumor homing of endogenous natural killer cells via therapeutic secretomes of chemically primed natural killer cells.

Cho S, Choi S, Maeng E, Park H, Ryu K, Park K J Immunother Cancer. 2025; 13(3).

PMID: 40044578 PMC: 11883546. DOI: 10.1136/jitc-2024-010371.

GPR132 regulates the function of NK cells through the Gαs/CSK/ZAP70/NF-κB signaling pathway as a potential immune checkpoint.

Hui X, Xue M, Ren Y, Chen Y, Chen X, Farooq M Sci Adv. 2025; 11(10):eadr9395.

PMID: 40043109 PMC: 11881902. DOI: 10.1126/sciadv.adr9395.

Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment.

In H, Park M, Lee H, Han K Antibodies (Basel). 2025; 14(1).

PMID: 39982231 PMC: 11843982. DOI: 10.3390/antib14010016.

References

Wang W, Erbe A, Hank J, Morris Z, Sondel P . NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015; 6:368. PMC: 4515552. DOI: 10.3389/fimmu.2015.00368. View

Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z . Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun. 2016; 7:13050. PMC: 5062608. DOI: 10.1038/ncomms13050. View

Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K . Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356(9244):1795-9. DOI: 10.1016/S0140-6736(00)03231-1. View

You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L . A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019; 9(1):64-78. PMC: 6356925. View

Cerwenka A, Lanier L . Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016; 16(2):112-23. DOI: 10.1038/nri.2015.9. View

Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T . Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011; 6(6):e20740. PMC: 3116834. DOI: 10.1371/journal.pone.0020740. View

Ditadi A, Sturgeon C, Keller G . A view of human haematopoietic development from the Petri dish. Nat Rev Mol Cell Biol. 2016; 18(1):56-67. DOI: 10.1038/nrm.2016.127. View

Tanaka Y, Nakazawa T, Nakamura M, Nishimura F, Matsuda R, Omoto K . Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. PLoS One. 2019; 14(3):e0212455. PMC: 6402639. DOI: 10.1371/journal.pone.0212455. View

Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H . Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017; 177(3):457-466. PMC: 5856008. DOI: 10.1111/bjh.14570. View

10.

Lee J, Kang T, Yoo W, Choi H, Jo S, Kong K . An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model. Cancer Immunol Res. 2018; 7(2):219-229. DOI: 10.1158/2326-6066.CIR-18-0317. View

11.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

12.

Abel A, Yang C, Thakar M, Malarkannan S . Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9:1869. PMC: 6099181. DOI: 10.3389/fimmu.2018.01869. View

13.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

14.

Vasu S, Berg M, Davidson-Moncada J, Tian X, Cullis H, Childs R . A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Cytotherapy. 2015; 17(11):1582-93. PMC: 7241296. DOI: 10.1016/j.jcyt.2015.07.020. View

15.

Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M . Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015; 13:277. PMC: 4548900. DOI: 10.1186/s12967-015-0632-8. View

16.

Hassan R, Ho M . Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2007; 44(1):46-53. PMC: 2265108. DOI: 10.1016/j.ejca.2007.08.028. View

17.

Sarvaria A, Jawdat D, Madrigal J, Saudemont A . Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications. Front Immunol. 2017; 8:329. PMC: 5362597. DOI: 10.3389/fimmu.2017.00329. View

18.

Guerra N, Tan Y, Joncker N, Choy A, Gallardo F, Xiong N . NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008; 28(4):571-80. PMC: 3528789. DOI: 10.1016/j.immuni.2008.02.016. View

19.

Knorr D, Ni Z, Hermanson D, Hexum M, Bendzick L, Cooper L . Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013; 2(4):274-83. PMC: 3659832. DOI: 10.5966/sctm.2012-0084. View

20.

Skeate R, Singh C, Cooley S, Geller M, Northouse J, Welbig J . Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products. Transfusion. 2012; 53(2):419-23. DOI: 10.1111/j.1537-2995.2012.03942.x. View